Trial Profile
A Randomized, Double-Blind, Phase 2 Study Evaluating the Safety of Same Day Versus Next Day Administration of Pegfilgrastim With Docetaxel, Doxorubicin, and Cyclophosphamide (TAC) in Women With Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Oct 2016
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary) ; Cyclophosphamide; Docetaxel; Doxorubicin
- Indications Breast cancer
- Focus Adverse reactions
- Sponsors Amgen
- 20 Oct 2016 New trial record